Viridian Therapeutics downgraded to Neutral from Buy at B. Riley

B. Riley downgraded Viridian Therapeutics to Neutral from Buy with a price target of $20, down from $25, post the Q1 report. The firm revised timelines for potential approvals, saying approval is still at least three years away. In addition, uncertainty remains if any dose-ranging work will needed for the pivotal trial, as the company is still awaiting official FDA minutes, the analyst tells investors in a research note.